In contrast, the PSA-blood-test failed to match the abnormal CTC test results in 83% of study participants, including 73% of men with prostate cancer (group PC), and 88% of the men screened (group ED) with positive PSA-marker-CTC and early prostate cancer diagnostic results. The gene discussed is KLK3; the disease is Familial prostate cancer.